2016第八届国际抗体大会

BIT's 8th Annual International Congress of Antibodies-2016

Theme: Accelerating the R&D of Next Generation Antibodies
Time: April 25-28, 2016
Place: Dalian, China

Program Layout 

Cluster 1: Main Conference 

Opening Ceremony and Keynote Forum

Track 1 Global Antibody Market Trend, Business and Partnering

Track 1-1 Promising Future and Challenge, Business and Cooperation in World Antibody Market

Track 1-2 Industry Aspects, Policy, Regulation, IP Issues, Business and Trends in Antibody Market

Track 1-3 IP Issues

Cluster 2: Scientific Program

Track 2 New Technologies and Trends in Antibody Research

Track 2-1: Novel Research in Immune System, Immunology and Immunogenicity of Antibodies

Track 2-2: Immunoglobulin Diversity, Antibody Characterization Technologies and Structure Biology

Track 2-3: Novel Antibody Library Technologies and Microarray Technologies, Nanotechnology, Biochips, Phage Display Technologies for Antibody Research

Track 2-4: Enabled High Throughput/Content Technologies for Antibody Research - From Antibody Screening, Selection to Optimization Technologies

Track 2-5: Antibody Humanization Technologies

Track 2-6: Exploiting the Immune System and Immunotherapeutic Strategies – from Vaccines to Cell-based and Protein Immunotherapy

Track 2-7: Glycoengineered Antibodies, Agonist and Super-agonist Antibodies

Track 2-8: Monovalent, Multivalent Antibodies, Fragments, Single-domain Antibody, and scFv

Track 3 Advances in Antibody Drug and Therapy

Track 3-1: Challenges and New Opportunities with Antibody and Protein Drugs

Track 3-2: Innovative Antibody drugs in Clinical Trail and Development

Track 3-3: Novel Antibody and Biologic Drug Targets

Track 3-4: Antibody-drug Conjugate (ADC) Discovery and Development

Track 3-5: Bispecific and Multispecific antibody discovery and development

Track 3-6: Next Generation of Cancer Immune therapy and Anti-Cancer Antibody

Track 3-7: Novel Therapeutic Antibodies for Infectious and Inflammatory Diseases

Track 3-8: Novel Therapeutic Antibodies for Allergy, Asthma and Autoimmune Diseases

Track 3-9: Antibodies for Pediatrics Diseases

Track 3-10: Therapeutic Antibodies for Neurological Disease and other Neglected Diseases

Track 4 Antibody Applications in Medical Diagnosis and other Non-Medical Field

Track 4-1: Novel Antibodies in Medical Treatment and Diagnosis

Track 4-2: Biomarker Development - Correlating with Antibody Therapy

Track 4-3: Antibodies for Immunohistochemistry and Immunofluorescence

Track 4-4: Antibody for Western Blot Analyses, ELISA and ELISPOT Techniques

Track 4-5: Antibody Research in Agriculture, Aquaculture, Veterinary and Food Sciences

Track 4-6: The “standardisation” of Methods Using Antibodies for the Detection of Diseases and other Issues

Track 5 Antibody Design, Engineering and Production

Track 5-1: Analytical Strategies for Early Phase Protein Engineering and New Antibody Formats

Track 5-2: Advances in Antibody Engineering and Design Strategies

Track 5-3: Cell Line and Model Organisms Development for Antibodies

Track 5-4: Novel Upstream Bioprocess Technologies in Antibody Production

Track 5-5: Optimised Platform for Downstream Processing of Antibodies

Track 5-6: Improved Purification and Modification Methods for Antibody Fragments

Track 5-7: Novel Expressing Platform for Antibody Production

Track 5-8: Biosimilars and Biobetters - Methods and Protocols

Cluster 3: Business and Career Development

Track 6: Antibody Business and Investment

Path 1301: Investment and Business Opportunities & Strategies of Antibodies

Path 1302: CRO of Antibody Discovery and Development

Path 1303: Antibody Project Matchmaking

Track7: Antibody Career Development

Path 1401: Talent Search for Big Pharma, Job Opportunity Briefing from Big Pharma

Path 1402: Academic Positions

Path 1403: Industrial Job Careers

Cluster 4: Posters and Exhibition

Zone 1: Basic Research of Antibody

Zone 2: Technology and Methodology Development

Zone 3: Antibody for Emerging and Severe Hard-to-Treat Diseases

Zone 4: New Product Launch Pavilion

Zone 5: Next Generation Antibody Affiliated Medical Devices and Reagents

Zone 6: Showcase for Antibody CROs